Krystal Biotech Inc (KRYS)
Receivables turnover
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Revenue | US$ in thousands | 296,569 | 55,764 | 498 | — | — |
| Receivables | US$ in thousands | 104,700 | 42,040 | — | — | — |
| Receivables turnover | 2.83 | 1.33 | — | — | — |
December 31, 2024 calculation
Receivables turnover = Revenue ÷ Receivables
= $296,569K ÷ $104,700K
= 2.83
The receivables turnover for Krystal Biotech Inc has shown improvement over the years. In December 2023, the receivables turnover ratio was 1.33, indicating that the company collected its accounts receivable approximately 1.33 times during that year. This may suggest that the company was able to efficiently convert its accounts receivable into cash.
By December 2024, the receivables turnover ratio further increased to 2.83, signifying a significant enhancement in the collection efficiency of Krystal Biotech Inc. The higher turnover ratio suggests that the company was able to collect its accounts receivable almost three times during that year. This improvement could reflect better credit policies, effective collection practices, and strong relationships with customers.
Overall, the increasing trend in receivables turnover from 2023 to 2024 indicates that Krystal Biotech Inc is managing its accounts receivable more efficiently, which could positively impact its cash flow and liquidity position.
Peer comparison
Dec 31, 2024